Dianthus Therapeutics, Inc. Common Stock
DNTH
$78.53
+0.55%
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation therapies for severe autoimmune diseases, with its lead asset Claseprubart positioned as a potential best-in-class complement therapeutic. As a small-cap, single-segment biotech with only 92 employees, Dianthus is a high-conviction, pipeline-driven story rather than a commercial-stage operator, deriving minimal revenue from licensing arrangements. The investor narrative is dominated by enthusiasm for Claseprubart's clinical prospects in complement-mediated autoimmune indications, reinforced by a major fund's $55 million stake disclosed in May 2026 amid a massive stock rally. At the same time, the stock has cooled sharply from its summer highs, with the market now debating whether the pullback represents a buying opportunity ahead of key data readouts or a signal that expectations had become overextended.…
DNTH
Dianthus Therapeutics, Inc. Common Stock
$78.53
Related headlines
Investment Opinion: Should I buy DNTH Today?
We assign a Hold rating on DNTH, balancing the unanimous strong buy consensus (15 analysts, average target $140.80, implying 70.9% upside) against the stock's extreme valuation (PS 765x) and deeply negative cash flow (-$155.7 million TTM). The core thesis is that Claseprubart's clinical potential is real but already substantially priced in, and the recent 23% pullback reflects a necessary cooling of expectations rather than a clear buying opportunity. Until data readouts provide clarity, the risk/reward is skewed by binary outcomes.
Supporting evidence for the Hold includes: (1) the stock's 137% one-year gain and 107.6% YTD return, which already reflect significant optimism; (2) a fortress balance sheet with debt-to-equity of 0.0028 and current ratio of 13.32, providing runway but not eliminating dilution risk; (3) revenue of just $761,000 in Q2 2026, up 294% YoY but from a tiny base, offering no fundamental support; and (4) the average analyst target of $140.80, which, while bullish, is offset by a wide target range ($122-$200) indicating high uncertainty. The forward PS ratio based on estimated revenue of $778.7 million would be approximately 2.0x, but that assumes successful commercialization, which is years away.
The biggest risks that could invalidate the thesis are: (1) clinical failure or delay for Claseprubart, which would likely send the stock toward its 52-week low of $32.22 (-61%); (2) continued cash burn requiring dilutive financing, with FCF at -$155.7 million TTM; and (3) competitive threats from established players like Argenx, especially after Sanofi's CIDP setback. We would upgrade to Buy if the stock pulls back to the $60-$70 range (improving risk/reward) or if positive Phase 3 data emerges; we would downgrade to Sell if Claseprubart shows safety signals or if cash runway drops below 12 months. Relative to its own history, the PS ratio of 765x is below the Q1 2026 peak of over 8,700x but far above 2022-2023 lows, suggesting the stock is still overvalued on current fundamentals.
Sign up to view all
DNTH 12-Month Price Forecast
DNTH presents a classic binary biotech investment case where the pipeline potential is substantial but already reflected in a premium valuation. The unanimous strong buy rating and $140.80 average target suggest significant upside, yet the 765x PS ratio and -$155.7 million free cash flow indicate that the market is pricing in flawless execution. The recent 23% pullback has reset sentiment, but the stock remains 137% higher year-over-year, and the low beta (0.181) means it will continue to trade on company-specific news. We would upgrade to bullish if Claseprubart demonstrates compelling efficacy in upcoming data readouts, and downgrade to bearish if safety concerns emerge or if the cash runway shortens materially. Given the wide target range ($122-$200) and high short interest, volatility is likely to persist, making position sizing critical.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Dianthus Therapeutics, Inc. Common Stock's 12-month outlook, with a consensus price target around $140.80 and implied upside of +79.3% versus the current price.
Average Target
$140.80
0 analysts
Implied Upside
+79.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$122 - $200
Analyst target range
Coverage is robust for a small-cap biotech, with 15 analysts covering DNTH and a consensus recommendation of "strong_buy" (recommendation mean of 1.06, where 1.0 is a strong buy). The average price target is $140.80, which implies roughly +70.9% upside from the current price of $82.37 — a strikingly bullish consensus. The distribution of recent institutional ratings is uniformly positive, with Truist, HC Wainwright, Wedbush, Evercore ISI, Baird, Clear Street, and Raymond James all maintaining Buy, Outperform, or Strong Buy ratings through 2026, and no downgrades or sell ratings appearing in the data. The consensus clearly leans strongly bullish, though the magnitude of the implied upside suggests the market price has decoupled from analyst expectations during the recent selloff. The target range is wide, from a low of $122.00 to a high of $200.00, a spread of $78 that signals meaningful uncertainty about the pipeline's ultimate value. The high target of $200 implies roughly +143% upside and would require substantial multiple expansion and/or highly favorable Claseprubart data, while even the low target of $122 assumes roughly +48% upside — notably, the lowest analyst target sits well above the current price, meaning every covering analyst sees the stock as undervalued at these levels. This unusually tight bullish skew, combined with the elevated short ratio of 15.0, sets up potential for a sharp squeeze if positive catalysts emerge, but the wide absolute target range and the stock's 23% one-month decline indicate that conviction, while directionally strong, is not uniform on magnitude.
Drowning in data?
Find the real signal!
Bulls vs Bears: DNTH Investment Factors
The bear case currently has stronger near-term evidence, given the 23% one-month decline, negative free cash flow of -$155.7 million, and an extreme PS ratio of 765x that offers no fundamental support. However, the bull case rests on a powerful long-term uptrend (+137% over one year), a fortress balance sheet with debt-to-equity of 0.0028, and unanimous analyst bullishness with a $140.80 average target implying 71% upside. The single most important tension is whether Claseprubart's clinical data will justify the premium valuation; positive readouts could trigger a violent short squeeze (short ratio 15.0), while any disappointment could send the stock toward its 52-week low of $32.22. With a beta of 0.181, DNTH is a pure pipeline story, and the market is effectively pricing in a high probability of success that may not be fully reflected in the recent price weakness.
Bullish
- Analyst Consensus Strong Buy with 71% Upside: All 15 covering analysts rate DNTH a strong buy (recommendation mean 1.06), with an average target of $140.80 implying +70.9% upside from $82.37. Even the lowest target of $122.00 sits 48% above the current price, indicating that every analyst views the recent selloff as an overreaction.
- Claseprubart Pipeline Optionality: Dianthus is developing Claseprubart as a potential best-in-class complement therapeutic for severe autoimmune diseases, a large and lucrative market. The $55 million stake taken by a major fund in May 2026, disclosed amid a 350% rally, signals high institutional conviction in the clinical data ahead.
- Fortress Balance Sheet with Minimal Debt: The company carries a debt-to-equity ratio of just 0.0028 and a current ratio of 13.32, leaving it with substantial liquidity after raising roughly $739 million in Q1 2026 and $274.5 million in Q3 2025. This cash runway reduces near-term financing risk and allows management to fund R&D aggressively without immediate dilution.
- Massive Long-Term Momentum Despite Pullback: DNTH is still up 137.04% over the past year and 107.59% year-to-date, massively outperforming SPY's 16.0% and 14.17% respective gains. The recent 23.05% one-month decline has reset sentiment while leaving the longer-term uptrend intact, potentially creating an attractive entry point.
Bearish
- Extreme Valuation with No Earnings Anchor: The trailing PS ratio is an extraordinary 764.98x and EV/Sales is 1,956.48x, with negative PE and EV/EBITDA. These multiples are far above typical clinical-stage biotech levels and price in flawless execution of Claseprubart's commercialization, leaving no margin for error.
- Deeply Negative Cash Flow and Rising Losses: Free cash flow is -$155.7 million TTM and -$49.2 million in Q2 2026 alone, while net loss widened to -$50.2 million from -$31.6 million a year earlier. R&D spend jumped to $48.7 million in Q2 2026 from $26.3 million, and the company will likely need further capital raises, creating dilution risk.
- Severe Recent Underperformance and Momentum Breakdown: DNTH is down 23.05% over the past month and 15.60% over three months, with relative strength versus SPY at -25.17% and -18.73% respectively. The stock has fallen from a 52-week high of $117.88 to $82.37, a 30% drawdown, signaling a distribution phase.
- Elevated Short Interest Amplifies Downside: A short ratio of 15.0 indicates heavy bearish positioning that could accelerate declines if negative news hits. While this creates squeeze potential, it also reflects significant skepticism about the pipeline's near-term prospects.
DNTH Technical Analysis
DNTH is in a powerful longer-term uptrend that has recently rolled over into a corrective phase. The stock is up 137.04% over the past year and 107.59% year-to-date, yet at $82.37 it sits only about 58.7% of the way up its 52-week range of $32.22 to $117.88, meaning it has surrendered a substantial portion of its earlier gains. That positioning — strong annual performance but a price well below the highs — suggests a momentum stock in a consolidation or distribution phase rather than a clean breakout candidate. Recent momentum is clearly negative and diverging from the longer-term trend. The stock is down 23.05% over the past month and 15.60% over three months, versus a 1-year gain of 137.04%, a sharp deceleration that signals the market is repricing the name lower. Relative strength versus SPY is -25.17% over one month and -18.73% over three months, confirming significant underperformance, while the 6-month change of -8.24% shows the weakness is not a one-month blip. With a short ratio of 15.0, short interest is elevated, which could amplify volatility in either direction. Key technical levels are the 52-week high of $117.88 as resistance and the 52-week low of $32.22 as deep support, with the recent consolidation around the high-$80s to low-$90s acting as an intermediate battleground. A decisive break below the recent $82-$85 area could open the door toward the mid-$70s, while reclaiming $95-$100 would be needed to re-establish upward momentum. Notably, the stock's beta of just 0.181 implies very low sensitivity to broad market moves — roughly 82% less volatile than SPY — meaning DNTH's price action is driven almost entirely by company-specific, pipeline-related catalysts rather than macro factors, which is critical for position sizing and risk management.
Beta
0.18
0.18x market volatility
Max Drawdown
-37.8%
Largest decline past year
52-Week Range
$32-$118
Price range past year
Annual Return
+134.8%
Cumulative gain past year
| Period | DNTH Return | S&P 500 |
|---|---|---|
| 1m | -20.2% | -1.2% |
| 3m | -24.4% | +3.4% |
| 6m | -10.1% | +7.0% |
| 1y | +134.8% | +14.4% |
| ytd | +97.9% | +12.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DNTH Fundamental Analysis
Dianthus is a pre-commercial biotech with a negligible and lumpy revenue base. Q2 2026 revenue was just $761,000, up 294.3% year-over-year from $193,000 in Q2 2025, but the entire top line comes from a single licensing segment, and quarterly revenue has oscillated between $284,000 and $1.326 million over the past several quarters. This is not a growth trajectory in any conventional sense — it reflects milestone and licensing timing rather than a scalable commercial engine, so the investment case rests entirely on Claseprubart's clinical and eventual commercial potential rather than current sales. The company is deeply unprofitable, with Q2 2026 net income of -$50.215 million and a net margin of -79.73%, alongside an operating margin of -87.39%. Gross margin is reported at 100%, but with cost of revenue at zero and revenue so small, this figure is not economically meaningful. The loss widened from -$40.834 million in Q1 2026 and -$31.629 million in Q2 2025, driven by rising R&D spend of $48.686 million in Q2 2026 versus $26.251 million a year earlier, reflecting heavy pipeline investment. The Q4 2025 net income of $97.905 million was an anomaly caused by $167.4 million in other income, not operational profitability. The balance sheet is exceptionally strong, with a debt-to-equity ratio of just 0.0028 and a current ratio of 13.32, and the company raised substantial capital — roughly $739 million in Q1 2026 financing and $274.5 million in Q3 2025 — leaving $110.7 million in cash at the end of Q2 2026 after deploying capital into investments. However, free cash flow is deeply negative at -$155.7 million TTM and -$49.2 million in Q2 2026 alone, with ROE of -32.90% and ROA of -17.69%, meaning the company is entirely dependent on external financing to fund operations and will likely need further raises, creating dilution risk for shareholders.
Quarterly Revenue
$761000.0B
2026-06
Revenue YoY Growth
+294.3%
YoY Comparison
Gross Margin
100.0%
Latest Quarter
Free Cash Flow
$-155709000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DNTH Overvalued?
Because Dianthus is unprofitable — trailing net income is negative and trailing EPS is -$0.10 — the PE ratio is not meaningful, and the appropriate primary metric is the price-to-sales ratio. The trailing PS ratio is an extraordinary 764.98x, and the forward PE of -17.86x remains negative, confirming that no near-term earnings-based valuation anchor exists. The gap between the trailing PS of ~765x and the forward-looking analyst revenue estimate of $778.7 million implies the market is pricing in a dramatic future inflection — essentially the successful commercialization of Claseprubart — rather than any current fundamental earnings power. Peer comparison is difficult given the absence of a clean industry average in the provided data, but a PS ratio near 765x is far above what is typical even for clinical-stage biotech, where high multiples are common. The EV/Sales ratio of 1,956.48x and negative EV/EBITDA of -9.31x underscore that enterprise value is being supported almost entirely by pipeline optionality and cash, not revenue. The premium is only justifiable if Claseprubart achieves best-in-class status in a large autoimmune market; any clinical disappointment would leave the valuation without fundamental support. Historically, DNTH's PS ratio has been extremely volatile, ranging from roughly 20x in late 2022 to over 8,700x in Q1 2026, and the current ~765x sits well below the Q1 2026 peak but far above the 2022-2023 lows. The price-to-book ratio of 3.16x is more moderate and reflects the large equity raises that have bolstered book value. Overall, the valuation is near the higher end of its own historical band on a sales basis, implying the market is pricing in optimistic pipeline outcomes, and the stock is vulnerable to sharp multiple compression if clinical or financing news disappoints.
PE
-9.8x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-9.3x
Enterprise Value Multiple
Investment Risk Disclosure
Dianthus faces significant financial and operational risks as a pre-revenue biotech. The company burned -$155.7 million in free cash flow over the trailing twelve months and -$49.2 million in Q2 2026 alone, with R&D expenses surging to $48.7 million from $26.3 million a year earlier. Despite a debt-to-equity ratio of just 0.0028 and a current ratio of 13.32, the company will likely need to raise additional capital to fund its pipeline, potentially diluting shareholders. Revenue is negligible at $761,000 in Q2 2026 and entirely dependent on a single licensing segment, providing no operational cushion. The net loss widened to -$50.2 million in Q2 2026 from -$31.6 million in Q2 2025, and with no commercial product, the company remains years away from profitability.
Market and competitive risks are amplified by DNTH's extreme valuation and binary clinical outlook. The stock trades at a trailing PS ratio of 764.98x and EV/Sales of 1,956.48x, leaving it highly vulnerable to multiple compression if pipeline data disappoints or if interest rates remain elevated, compressing biotech multiples. The beta of 0.181 suggests low correlation to broad market moves, but this also means the stock is entirely at the mercy of company-specific news, and the short ratio of 15.0 indicates significant bearish bets that could exacerbate volatility. Recent news of Sanofi's CIDP trial setback may benefit competitors like Argenx, highlighting the competitive intensity in complement-mediated autoimmune diseases. Additionally, the stock's 23.05% one-month decline and -25.17% relative strength versus SPY underscore how quickly sentiment can reverse in this sector.
The worst-case scenario for DNTH would be a clinical failure or delay for Claseprubart, combined with a broader biotech selloff. In such a scenario, the stock could retest its 52-week low of $32.22, representing a -60.9% decline from the current price of $82.37. Even the analyst low target of $122.00 is 48% above the current price, but if the pipeline fails, those targets would be slashed, and the stock could fall below the 52-week low. The maximum drawdown over the past 180 days was -28.97%, but a binary event could cause a much sharper decline. Investors could lose more than half their capital if Claseprubart fails to demonstrate efficacy or safety in ongoing trials.
FAQ
The most severe risk is clinical failure or delay for Claseprubart, which could send the stock toward its 52-week low of $32.22, a -61% decline. Financial risk is also high, with free cash flow at -$155.7 million TTM and a likely need for dilutive financing, despite a strong balance sheet (debt-to-equity 0.0028). Competitive risk is rising, as Argenx's Vyvgart may dominate the CIDP market following Sanofi's setback, potentially limiting Claseprubart's commercial opportunity. Finally, valuation risk is extreme: the 765x PS ratio leaves no room for error, and any negative news could trigger a sharp multiple compression. These risks are ranked in order of severity: clinical, financial, competitive, and valuation.
Our 12-month forecast for DNTH includes three scenarios: a bull case (30% probability) targeting $140-$200, driven by positive clinical data and a short squeeze; a base case (50% probability) targeting $100-$140, assuming incremental progress and stabilization around the analyst average of $140.80; and a bear case (20% probability) targeting $32-$80, triggered by clinical failure or competitive pressure. The base case is most likely, hinging on the assumption that Claseprubart shows promising but not definitive efficacy, allowing the stock to trade in a range. The wide target range reflects the binary nature of the investment, and the high short interest (15.0) could amplify moves in either direction.
DNTH appears significantly overvalued on current fundamentals, with a trailing PS ratio of 764.98x and EV/Sales of 1,956.48x, both far above typical clinical-stage biotech levels. The company has negligible revenue of $761,000 in Q2 2026 and negative earnings, so traditional valuation metrics are not meaningful. However, the forward PS ratio based on estimated 2027 revenue of $778.7 million would be approximately 2.0x, implying the market is pricing in a dramatic future inflection. Relative to its own history, the current PS is below the Q1 2026 peak of over 8,700x but well above the 2022-2023 lows of around 20x. The stock is undervalued only if Claseprubart succeeds; otherwise, it is vastly overvalued.
DNTH is a high-risk, high-reward biotech that may be a good buy only for investors with a high tolerance for volatility and a long-term horizon. The stock has 70.9% upside to the analyst average target of $140.80, and all 15 analysts rate it a strong buy, but the valuation is extreme at 765x trailing sales and the company is burning -$155.7 million in free cash flow annually. The recent 23% one-month decline has improved the entry point, but the binary nature of clinical trials means the stock could easily halve if data disappoints. For those who believe in the Claseprubart story, a small, diversified position may be warranted, but it is not a suitable core holding.
DNTH is more suitable for long-term investment (minimum 2-3 years) for investors who can tolerate binary risk and believe in the Claseprubart pipeline, as clinical trials and potential commercialization take years to unfold. The stock's low beta (0.181) and lack of dividends make it a poor short-term trading vehicle, but its high short ratio (15.0) and recent volatility (-23% in one month) offer trading opportunities for those with high risk tolerance. For long-term holders, the key is to monitor cash burn and clinical milestones, as the company will likely need to raise capital, potentially diluting shareholders. A suggested minimum holding period is 18-24 months to allow for data readouts and potential partnerships.